Skip to main content

Table 2 Comparison of clinico-pathological variables between TNBC and non-TNBC patients overexpressing or not BRCA1-IRIS (aka IRIS)

From: The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion

Menopausal IRIS-positive IRIS-negative χ2 P-value Total
Pre TNBC 14 (74%) TNBC 5 (26%) 6.15 0.013 19
  Non-TNBC 9 (36%) Non-TNBC 16 (64%)   25
Post TNBC 14 (58%) TNBC 10 (42%) 7.44 0.0064 24
  Non-TNBC 6 (21%) Non-TNBC 22 (79%)   28
Total   43   53    96
Tumor size IRIS-positive IRIS-negative χ2 P-value  
≤5 cm TNBC 21 (91%) TNBC 2 (9%) 28.46 <0.000001 23
  Non-TNBC 9 (22%) Non-TNBC 32 (78%)   41
>5 cm TNBC 12 (60%) TNBC 8 (40%) 0.31 0.5809 20
  Non-TNBC 6 (50%) Non-TNBC 6 (50%)   12
Total   43   53    96
Grade IRIS-positive IRIS-negative χ2 P-value  
1 + 2 TNBC 23 (70%) TNBC 10 (30%) 13.84 0.0002 33
  Non-TNBC 13 (28%) Non-TNBC 34 (72%)   47
3 TNBC 5 (62%) TNBC 3 (38%) 0.63 0.4285 8
  Non-TNBC 2 (40%) Non-TNBC 3 (60%)   5
Total   43   50    93
Stage IRIS-positive IRIS-negative χ2 P-value  
II TNBC 8 (80%) TNBC 2 (20%) 7.25 0.0071 10
  Non-TNBC 9 (31%) Non-TNBC 20 (69%)   29
III + IV TNBC 16 (67%) TNBC 8 (33%) 7.14 0.0075 24
  Non-TNBC 6 (27%) Non-TNBC 16 (73%)   22
Total   39   46    85
Lymph-node IRIS-positive IRIS-negative χ2 P-value  
Present TNBC 25 (76%) TNBC 8 (24%) 17.28 <0.000001 33
  Non-TNBC 7 (23%) Non-TNBC 23 (77%)   30
Absent TNBC 4 (40%) TNBC 6 (60%) 0.29 0.5922 10
  Non-TNBC 7 (30%) Non-TNBC 16 (70%)   23
Total   43   53    96